- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
Advance Nanotech Senior VP to lead biopharma seminar at University of Massachusetts Boston
New York City | Posted on April 25, 2006
Advance Nanotech, Inc., (OTC BB:AVNA.OB - News), the premier provider of financing and support services to expedite the commercialization of nanotechnology discoveries, today announced that Dr. Michael Helmus, senior vice president, BioPharma, will lead a seminar on Monday, April 24 on Commercializing Nanotechnology in BioPharma Applications. The seminar is sponsored by the Biology and Chemistry Departments of the University of Massachusetts, and will take place at the University’s Boston campus.
Who – Dr. Michael Helmus, senior vice president, BioPharma at Advance Nanotech will lead a seminar on Commercializing Nanotechnology in BioPharma Applications. Dr. Helmus currently serves on the University of Massachusetts Boston Science Advisory Board.
What – Spring 2006 Biology Seminar Series.
When – Monday, April 24 at 2:30 pm.
Where – University of Massachusetts, Boston Campus, Science Building, Small Science Auditorium, First Floor, Room S/1/006.
Why – The seminar will explore progress in the uses of nanotechnology in BioPharma Applications.
For more information on the seminar or to schedule a press briefing with Helmus, please contact Derek Brookmeyer at 415.623.2076. For more information about the seminar series, go to www.bio.umb.edu/events.
About Michael Helmus, Ph.D.
Dr. Helmus assumed the position of senior vice president, BioPharma at Advance Nanotech in August 2005. Dr. Helmus is responsible for managing all of the firm’s partnerships and investments related to the biopharma and life sciences fields. Before joining Advance Nanotech Dr. Helmus served as the Vice President, Advanced Biomaterials at Boston Scientific. Prior to that Dr. Helmus held research and development positions with organizations including Edwards Lifesciences, Baxter CVS, Pfizer, and Arthur D. Little. Dr. Helmus holds a PhD and an MS in Biomedical Engineering from Case Western Reserve University and a BS in Metallurgy and Materials Science from Lehigh University. Dr. Helmus’ expertise includes the identification and acquisition of new technologies, implementation and management of research and development programs, and intellectual property development and management. In the course of his career Dr. Helmus has been issued 26 U.S. patents, authored 47 technical publications and written 29 technology and market assessments.
About Advance Nanotech:
Advance Nanotech is dedicated to the successful commercialization of disruptive nanotechnologies to produce nano-enabled products. Advance provides financing and support services including commercialization guidance, project and infrastructure management, leadership assets, and counsel on intellectual property, licensing and regulatory issues to ensure maximum market potential. Advance Nanotech's diversified portfolio of 26 nanotechnologies, of which the company holds a majority stake in 21, impacts a range of applications including, but not limited to, sensors, medical therapeutics and composites. Advance is forging partnerships with leading manufacturers and universities in Europe, Asia and North America to transform innovative nanotechnology concepts into practical solutions.
For more information, please click here.This document contains forward-looking statements by Advance Nanotech regarding its expectations as to its business, and involves risks and uncertainties and may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
Iran to hold intl. school on application of nanomaterials in medicine September 20th, 2016
Chains of nanogold – forged with atomic precision September 23rd, 2016
Nanotech Grants Options September 22nd, 2016
Coffee-infused foam removes lead from contaminated water September 21st, 2016